The effects of Nigella sativa on thyroid function, serum Vascular Endothelial Growth Factor (VEGF) – 1, Nesfatin-1 and anthropometric features in patients with Hashimoto’s thyroiditis: a randomized controlled trial

Table 3 Metabolic parameters in treatment groups before and after intervention

N	Nigella sativa	Placebo	P†
N	N = 20	N = 20	P†
TSH (mIU/l)
Before	6.42 ± 3.86	8.14 ± 7.28	0.35
After	4.13 ± 2.35	8.27 ± 7.21	0.02
P‡	0.03	0.40
T3 (mmol/l)
Before	0.92 ± 0.27	1.18 ± 0.36	0.017
After	1.06 ± 0.34	1.16 ± 0.35	0.39
P‡	0.008	0.15
T4 (mmol/l)
Before	8.07 ± 2.56	7.97 ± 3.11	0.91
After	8.89 ± 1.43	7.63 ± 2.23	0.04
P‡	0.21	0.32
Anti-TPO (IU/ml)
Before	294.55 ± 210.05	278.10 ± 170.77	0.78
After	147.99 ± 158.33	274.30 ± 167.20	0.01
P‡	0.019	0.28
Nesfatin-1 (ng/ml)
Before	41.80 ± 28.33	25.86 ± 20.91	0.049
After	37.63 ± 5.91	26.75 ± 23.95
P‡	0.34	0.69
VEGF (ng/L)
Before	3521.13 ± 395.95	2101.73 ± 339.29	0.17
After	2100.17 ± 36,082	2100.17 ± 360.82	0.25
P‡	0.02	0.99

Data are presented as mean ± SD. † P values for ANOCOVA after adjustment for age, gender and baseline concentration of parameter; ‡P values for paired t-test. TSH, thyroid-stimulating hormone; T3 triiodothyronine, T4 thyroxine, VEGF vascular endothelial growth factor, the bolded P values are statistically significant

ISSN: 2662-7671